FY2025 EPS Estimates for Arcellx Cut by Cantor Fitzgerald

Arcellx, Inc. (NASDAQ:ACLX) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Arcellx in a report issued on Wednesday, November 26th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings of ($3.96) per share for the year, down from their previous forecast of ($3.72). Cantor Fitzgerald has a “Hold” rating and a $88.00 price target on the stock. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx’s FY2026 earnings at ($1.52) EPS.

Arcellx (NASDAQ:ACLX) last released its earnings results on Wednesday, November 5th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.03). The firm had revenue of $4.95 million for the quarter, compared to the consensus estimate of $11.24 million. Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%.

A number of other research firms also recently commented on ACLX. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcellx in a report on Wednesday, October 8th. Wolfe Research started coverage on shares of Arcellx in a research note on Tuesday, November 18th. They set a “peer perform” rating on the stock. Stifel Nicolaus set a $129.00 target price on Arcellx and gave the company a “buy” rating in a research note on Thursday, October 16th. Finally, Canaccord Genuity Group upped their target price on Arcellx from $121.00 to $130.00 and gave the company a “buy” rating in a report on Monday, November 3rd. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $115.50.

Arcellx Trading Down 0.8%

Shares of NASDAQ ACLX opened at $72.69 on Monday. The company has a market capitalization of $4.20 billion, a price-to-earnings ratio of -18.49 and a beta of 0.34. Arcellx has a twelve month low of $47.86 and a twelve month high of $96.39. The business has a 50 day simple moving average of $84.78 and a 200-day simple moving average of $74.20.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 21,034 shares of the company’s stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $81.28, for a total value of $1,709,643.52. Following the completion of the transaction, the insider owned 624 shares in the company, valued at approximately $50,718.72. This represents a 97.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 37,486 shares of company stock worth $3,030,736. Insiders own 8.35% of the company’s stock.

Hedge Funds Weigh In On Arcellx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Teacher Retirement System of Texas increased its holdings in shares of Arcellx by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock valued at $585,000 after buying an additional 151 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Arcellx by 7.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,428 shares of the company’s stock worth $226,000 after acquiring an additional 228 shares in the last quarter. CWM LLC grew its holdings in shares of Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after acquiring an additional 251 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Arcellx by 9.0% during the third quarter. Integrated Wealth Concepts LLC now owns 3,423 shares of the company’s stock worth $281,000 after purchasing an additional 283 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arcellx by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,129 shares of the company’s stock valued at $140,000 after purchasing an additional 290 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors and hedge funds.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).